Short Interest in Burning Rock Biotech Limited (NASDAQ:BNR) Decreases By 30.2%

Burning Rock Biotech Limited (NASDAQ:BNR) was the recipient of a significant drop in short interest in October. As of October 31st, there was short interest totalling 84,000 shares, a drop of 30.2% from the October 15th total of 120,300 shares. Based on an average daily volume of 30,600 shares, the short-interest ratio is currently 2.7 days. Approximately 1.0% of the company’s stock are short sold.

Burning Rock Biotech Price Performance

Shares of NASDAQ BNR opened at $3.56 on Thursday. The stock has a market capitalization of $36.45 million, a P/E ratio of -0.74 and a beta of 0.14. The business has a fifty day moving average price of $3.37 and a 200 day moving average price of $5.69. Burning Rock Biotech has a 1-year low of $2.62 and a 1-year high of $10.20.

Burning Rock Biotech (NASDAQ:BNR) last released its quarterly earnings results on Thursday, August 22nd. The company reported ($0.14) earnings per share (EPS) for the quarter. Burning Rock Biotech had a negative return on equity of 74.96% and a negative net margin of 111.25%. The firm had revenue of $18.65 million during the quarter.

Hedge Funds Weigh In On Burning Rock Biotech

A hedge fund recently bought a new stake in Burning Rock Biotech stock. SkyView Investment Advisors LLC bought a new position in shares of Burning Rock Biotech Limited (NASDAQ:BNR) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 10,000 shares of the company’s stock, valued at approximately $64,000. SkyView Investment Advisors LLC owned about 0.10% of Burning Rock Biotech at the end of the most recent quarter. Institutional investors and hedge funds own 30.03% of the company’s stock.

About Burning Rock Biotech

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.